US FDA approves Revolution Medicines' pancreatic cancer drug
The once-daily pill improved median overall survival to 13.2 months in a 500-patient trial, compared with 6.7 months for chemotherapy.
- On Aug 26, The FDA approved Rasonque, a new drug from Revolution Medicines for adults with advanced pancreatic cancer who have received prior treatment.
- Designed as a once-daily pill, Rasonque functions by blocking several forms of the RAS protein, which drives tumor growth in pancreatic cancer.
- Data from a study of 500 adults showed the drug improved median overall survival to 13.2 months, compared with 6.7 months on standard chemotherapy.
- Andrew Ko, a medical oncologist at the University of California, San Francisco, called it "the biggest development we've had in pancreas cancer in decades."
- Revolution did not immediately respond to a request from Reuters for comment on the drug's pricing and availability following the regulatory clearance.
86 Articles
86 Articles
Revolution Medicines has obtained early regulatory approval in the United States for daraxonrasib, a daily tablet for pancreatic cancer, pointed out by a former member of the American Congress and cancer patient as a miracle medicine. Exclusive material for subscribers. To have full access, access the link of the subject and register.
The rasonque has undergone several clinical trials, in which it almost doubled the average life span in the face of conventional chemotherapy. It is intended for patients whose cancer has already spread throughout the body.
FDA Approves New Drug for Pancreatic Cancer
Federal regulators on Aug. 26 said they approved a new drug for the most common form of pancreatic cancer. The drug, known as Rasonque and daraxonrasib, is approved to treat a cancer type responsible for about nine in 10 new pancreatic cancer cases diagnosed in the United States each year. The approval was based in part on a phase 3 randomized, open-label clinical trial of 500 adults who had previously received treatment for the pancreatic cance…
The Pill That Just Cut the Deadliest Cancer's Death Risk by 60% Finally Got FDA's Yes
A once-daily cancer pill that cut the risk of death by 60 per cent in patients with advanced pancreatic cancer has been approved in the US, nearly doubling median survival compared with standard chemotherapy. The FDA cleared Rasonque, also known as Daraxonrasib, on Wednesday for adults with previously treated metastatic pancreatic ductal adenocarcinoma, offering a new option for people facing one of the world's deadliest cancers. In the pivotal …
Revolution Medicines gets FDA approval for targeted pancreatic cancer drug
The drug, branded as Rasonque and also known as daraxonrasib, is a once-daily pill designed to block several forms of the RAS protein, which helps drive tumor growth in many pancreatic cancers.
Coverage Details
Bias Distribution
- 68% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
